Alume Biosciences
PrivateLast Round
Seed Round
Apr 6, 2026
Total Funding Raised
$24.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Alume Biosciences is a biotechnology company that develops nerve illumination technology designed to make nerves visible to surgeons during operations.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials, Medical Imaging
Business Model
B2B
Customer Profile
Usage-Based SaaS, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alume Biosciences Comparables
Compare Alume Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trace Biosciences | 91% | |
| Illuminare Biotechnologies | 86% | |
| Bracco S.p.A. | 77% | |
Alume Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Apr 6, 2026 | ||||
| Series B | Jan 10, 2023 | ||||
| Grant | Sep 9, 2022 | ||||
| Grant | Dec 15, 2020 | ||||
| Series A | May 1, 2020 | ||||
Grant | Apr 5, 2019 |
Alume Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| National Institute of Neurological Disorders and Stroke | Grant |
| Small Business Administration | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 6, 2026
$110K Seed Round raised.
- Feb 18, 2025
Kaveri Parker appointed as the new Chief Business Officer.
Alume Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |